Heart failure & cardiomyopathies
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity Heart Failure with Preserved Ejection Fraction (HFpEF) Phenotype
Authors' conclusion
In total, STEP-HFpEF program randomized 1,146 participants with the obesity phenotype of HFpEF
Study context
- Population
- Adults with HFpEF (left ventricular ejection fraction (LVEF) ≥45%, NYHA II–IV, KCCQ-CSS <90) and BMI ≥30 kg/m², with or without T2DM529 STEP-HFpEF
- Participants
- 1,146 adults
- Comparison
- Semaglutide 2.4 mg once weekly vs placebo
- Primary endpoint
- Dual: change in KCCQ-CSS and body weight
- Follow-up
- 52 weeks
Methodological detailsinternational, multicentre, double-blind, placebo-controlled
- International
- Multicentre
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Baseline characteristics
- Women
- nearly half
- Median BMI
- 37 kg/m²
- Median LVEF
- 57%
- SGLT2 inhibitor use in STEP-HFpEF DM
- 32%
- SGLT2 inhibitor use in STEP-HFpEF
- rare
- MRA use
- approximately one-third
- KCCQ-CSS
- ∼59 points
- 6-minute walking distance
- ∼300 m
Original publication
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. JACC Heart Fail. Published 21 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →